Unknown

Dataset Information

0

Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.


ABSTRACT: AIM:To determine the projected impact of a multigene pharmacogenetic (PGx) test on medication prescribing. MATERIALS & METHODS:A retrospective analysis was conducted with 122 cardiac catheterization laboratory patients undergoing angiography for eligibility of potential PGx-guided interventions that could have occurred if multigene PGx information was pre-emptively available at the time of the procedure. Medication data and presence of actionable at-risk genotypes were used to determine eligibility of a PGx intervention. RESULTS:20% of the study population (n = 24) would have qualified for at least one PGx-based medication intervention per US FDA or Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines within 6 months of their cardiac catheterization procedure. Commonly encountered gene-drug pairs for these interventions included: CYP2C19 for clopidogrel and antidepressants, CYP2D6 for antidepressants and codeine, SLCO1B1 for simvastatin, and VKORC1/CYP2C9 for warfarin. CONCLUSION:Pre-emptive use of a multigene PGx test in the cardiac catheterization laboratory offers potential to reduce adverse medication outcomes.

SUBMITTER: Dong OM 

PROVIDER: S-EPMC6367721 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC6951851 | BioStudies
2017-01-01 | S-EPMC5585983 | BioStudies
2019-01-01 | S-EPMC6764327 | BioStudies
2020-01-01 | S-EPMC7560181 | BioStudies
2020-01-01 | S-EPMC6977333 | BioStudies
| S-EPMC4451573 | BioStudies
2015-01-01 | S-EPMC4567688 | BioStudies
| S-EPMC7505210 | BioStudies
2020-01-01 | S-EPMC7696803 | BioStudies
2017-01-01 | S-EPMC5207784 | BioStudies